Global Plantar Fasciitis Treatment Market Overview
As per MRFR analysis, the Plantar Fasciitis Treatment Market Size was estimated at 2.26 (USD Billion) in 2024. The Plantar Fasciitis Treatment Market Industry is expected to grow from 2.79 (USD Billion) in 2025 to 18.66 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 23.50% during the forecast period (2025 - 2034). Growing population, growing incidence of plantar fasciitis, and increasing awareness and early diagnosis are the key market drivers boosting the expansion of the market.

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review
July 2023: As North Star Vascular & Interventional launched, they presented an innovative non-invasive technique for treating plantar fasciitis - the plantar fasciitis embolization. This offers a substantially effective solution to those seeking non-invasive treatments. Â
October 2022: One of the biggest news about treating plantar fasciitis is the acquisition of Hanger Inc. by Patient Square Capital, intended for a staggering $1.25 billion. This purchase will accelerate Hanger's growth targets, especially in value-based care innovation, including medical devices like ankle-foot orthoses and AFOs that help treat plantar fasciitis. Â
September 2022: Aetrex Inc. launched their Foot.com Data Portal, allowing global shoe producers to create better-fitting shoes.
Plantar Fasciitis Treatment Market Trends
The increasing incidence of obesity is driving the market growth
Market CAGR for Plantar Fasciitis Treatment is being driven by the increasing incidence of obesity. Foot pain resulting from repetitive strain injuries is frequently attributed to planter fasciitis. The sole becomes painful as a result of it affecting the heel area of the foot. This kind of inflammation is specific to muscles. People who spend a lot of time standing on hard surfaces are more likely to experience it. Activities involving foot stretches assist people in reducing their plantar fasciitis pain. Planter fasciitis is a condition that pains the foot when walking because of inflammation and irritation of the strong band of tissue supporting the arch of the foot.
Additionally, An increase in the number of occurrences with plantar fasciitis and a rise in the use of orthotics are driving the   market. The potential for growth for stakeholders is increased by the fact that a variety of treatments are becoming a strong ally in the battle against severe heel pain brought on by plantar fasciitis. Additionally, since obese people are more likely to get plantar fasciitis, the growing obesity population is fueling the market's expansion. In a study published in The Journal of Pain, the National Centre for Integrative and Complementary Health (NCCIH) found a substantial correlation between plantar fasciitis and body mass index (BMI).
Growing older is a risk factor for plantar fasciitis to occur, and as the world's population becomes older, the number of people who will likely develop foot-related problems rises, increasing the need for treatment options. Increased physical activity, obesity, and changing lifestyles are some of the causes linked to the rising occurrence of plantar fasciitis, which is driving up demand for treatment solutions. Plantar fasciitis treatment options are becoming less intrusive and more successful due to ongoing improvements in medical technologies, including novel treatment modes and therapies. Plantar fasciitis and other foot-related injuries are becoming more common as a result of increased involvement in sports and physical activities. The need for efficient treatment alternatives among athletes and active people is driving market expansion.
For instance, The Centers for Prevention and Control of Diseases (CDC) released revised data in January 2022, showing that 40,698 individuals died in automobile accidents in 2020, compared to 200,995 deaths from unintentional injuries. The same data indicates that in 2020, there were 97.9 million trips to emergency rooms and 24.8 million visits to physicians in the US. Thus, result in driving the Plantar Fasciitis Treatment market revenue.
Plantar Fasciitis Treatment Market Segment Insights
Plantar Fasciitis Treatment Type Insights
The   Plantar Fasciitis Treatment market segmentation, based on type includes Medication Therapy, Oral, Parenteral, Orthotics, Shockwave Therapy, Surgery, Intracorporeal Pneumatic Shockwave Therapy, and Others. The Medication Therapy segment dominated the market, Medication therapy is often considered a non-invasive or minimally invasive treatment option compared to surgical interventions, this appeals to individuals who prefer conservative measures before considering more aggressive treatment.
Plantar Fasciitis Treatment Treatment Type Insights                                        Â
The   Plantar Fasciitis Treatment market segmentation, based on Treatment Type, includes Pharmacological Treatment, Orthotic Devices, Shockwave Therapy, Surgery, and Other Treatment Types. Over the course of the projection period, the Orthotic Devices segment is anticipated to dominate. Orthotic devices, or orthoses as they are more widely called, are braces that help support weaker muscles while walking and running. Additionally, they aid in enhancing comfort and delaying the development of contractures, which are shortened over time due to constricted muscles or tendons. It is possible to wear orthotic devices day or night. The patient's condition determines the type of orthotic device that should be utilized.
Plantar Fasciitis Treatment End-User Insights
The   Plantar Fasciitis Treatment market segmentation, based on end user, includes Hospitals, Clinics, and Others. The Hospitals category generated the most income. because plantar fasciitis symptoms including pain and inflammation are best treated with the most often used kind of treatment.
Figure1: Â Plantar Fasciitis Treatment Market, by Distribution channel,2023 & 2032(USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Plantar Fasciitis Treatment Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Plantar Fasciitis Treatment market area will dominate this market. The need for efficient therapies is exacerbated by plantar fasciitis's high incidence in North America. Plantar fasciitis is more common in older people, obese people, and people who engage in particular physical activities.
Further, the major countries studied in the market report are The US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.
Figure2:Â Â Plantar Fasciitis Treatment Market Share By Region 2023 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe Plantar Fasciitis Treatment market has the second-largest portion of the market, as a result of a rise in lifestyle-related factors' incidence and growing awareness of their diagnosis. Further, the German Plantar Fasciitis Treatment market had the biggest market share, and the UK Plantar Fasciitis Treatment market was the fastest growing market in the European region
The Asia-Pacific Plantar Fasciitis Treatment Market is anticipated to expand between 2025 and 2034 at the quickest CAGR. This is because of the rise in sports and physical activity as well as easier access to healthcare. Moreover, China’s Plantar Fasciitis Treatment market had the biggest market share, and the Indian Plantar Fasciitis Treatment market was the fastest growing market in the Asia-Pacific region.
Plantar Fasciitis Treatment Key Market Players& Competitive Insights
Leading market players are putting a lot of money on R&D to expand their product lines, which will help the market for weight reduction products grow. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. to grow and endure in an increasingly cutthroat and dynamic market, Plantar Fasciitis Treatment industry must provide reasonably priced goods.
Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the Plantar Fasciitis Treatment industry to help customers and expand the market segment. In recent years, the Plantar Fasciitis Treatment industry has provided some of the biggest benefits to medicine. Major players in the Plantar Fasciitis Treatment market, including Bayer AG (Germany), SUPERFEET WORLDWIDE, LLC (U.S.), Bauerfeind USA Inc. (Germany), Ottobock (Germany), Recover Sports Medicine (Australia), Shapecrunch (India), and others, are attempting to increase market demand by investing in research and development operations.
One of the biggest pharmaceutical and biomedical corporations in the world is Bayer AG, a multinational pharmaceutical and biotechnology firm based in Germany. Bayer, which has its headquarters in Leverkusen, is a company that deals in pharmaceuticals, consumer healthcare goods, seeds, agricultural chemicals, and biotechnology products. The business is included in the EURO STOXX 50 index of stock market companies. In June 2021, The business declared that it has acquired PSMA Therapeutics Inc. and Noria Therapeutics Inc., acquiring the rights to several actinium-225-based cancer-based experimental drugs.
Orthopedic technology is the business of Ottobock SE & Co. KGaA, formerly known as Otto Bock, a German corporation with its headquarters located in Duderstadt. It is regarded as the   market leader in the prosthetics industry and a top supplier of exoskeletons, wheelchairs, and orthotics. Max Näder started his studies at Ottobock as an industrial clerk and orthopedic mechanic. He wed Marie Bock, the businesswoman's younger sister, in 1943 while on military leave. The corporation used forced laborers in World War II. In December 2019, Ottobock will receive up to €100 million from the European Investment Bank (EIB) to aid in the development of new products by the company.
Key Companies in the Plantar Fasciitis Treatment market include
- SUPERFEET WORLDWIDE LLC (U.S.)
- Bauerfeind USA Inc. (Germany)
- Recover Sports Medicine (Australia)
- Apothecary Products, LLC (U.S.)
- Ellis & Badenhausen (U.S.)
- SYNXSOLE PTY LTD. (Australia)
- Revance Therapeutics, (U.S.)
Plantar Fasciitis Treatment Market Industry Developments
-
Q1 2024: OrthoFeet Launches New Plantar Fasciitis Relief Orthotic Insole OrthoFeet announced the launch of a new orthotic insole specifically designed for plantar fasciitis relief, expanding its product portfolio for foot pain management.
-
Q2 2024: Heel That Pain Receives FDA Clearance for New Plantar Fasciitis Medical Device Heel That Pain received FDA clearance for its latest medical device aimed at treating plantar fasciitis, enabling broader distribution in U.S. clinics.
-
Q2 2024: BioElectronics Corporation Announces Partnership with Leading Podiatry Group for Plantar Fasciitis Therapy BioElectronics Corporation entered into a partnership with a major podiatry group to promote and distribute its wearable therapy device for plantar fasciitis treatment.
-
Q3 2024: Zentoes Expands Manufacturing Facility to Meet Growing Demand for Plantar Fasciitis Products Zentoes announced the opening of a new manufacturing facility to increase production capacity for its plantar fasciitis treatment products.
-
Q3 2024: TheraSole Secures $10 Million Series A Funding to Accelerate Plantar Fasciitis Device Development TheraSole raised $10 million in Series A funding to support the development and commercialization of its novel plantar fasciitis treatment device.
-
Q4 2024: Stridex Medical Appoints New CEO to Lead Plantar Fasciitis Product Expansion Stridex Medical announced the appointment of a new CEO to oversee the expansion of its plantar fasciitis treatment product line.
-
Q4 2024: Footlogics Launches Next-Generation Orthotic for Plantar Fasciitis Footlogics introduced a next-generation orthotic device designed to provide enhanced support and pain relief for plantar fasciitis sufferers.
-
Q1 2025: SoleScience Partners with National Retail Chain to Distribute Plantar Fasciitis Insoles SoleScience entered into a distribution partnership with a national retail chain to offer its plantar fasciitis insoles across hundreds of stores.
-
Q1 2025: PediTech Receives CE Mark Approval for Innovative Plantar Fasciitis Treatment Device PediTech received CE Mark approval for its new device targeting plantar fasciitis, paving the way for commercialization in European markets.
-
Q2 2025: OrthoCare Acquires Sole Relief to Expand Plantar Fasciitis Treatment Portfolio OrthoCare completed the acquisition of Sole Relief, strengthening its portfolio of products for plantar fasciitis treatment.
-
Q2 2025: HeelEase Announces $5 Million Seed Funding for Plantar Fasciitis Therapy Innovation HeelEase secured $5 million in seed funding to advance research and development of its proprietary plantar fasciitis therapy.
-
Q3 2025: ArchMed Opens New R&D Center Focused on Plantar Fasciitis Solutions ArchMed inaugurated a new research and development center dedicated to innovating treatments for plantar fasciitis.
Plantar Fasciitis Treatment Market Segmentation
Plantar Fasciitis Treatment Type Outlook
- Intracorporeal Pneumatic Shockwave Therapy
Plantar Fasciitis Treatment Treatment Type Outlook
- Pharmacological Treatment
Plantar Fasciitis Treatment End-User Outlook
Plantar Fasciitis Treatment Regional Outlook
Report Attribute/Metric |
Details |
Market Size 2024
|
  2.26 (USD Billion)
|
Market Size 2025
|
  2.79 (USD Billion)
|
Market Size 2034
|
 18.66 (USD Billion)
|
Compound Annual Growth Rate (CAGR)
|
 23.50 % (2025 - 2034)
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
Base Year
|
2024
|
Market Forecast Period
|
2025 - 2034
|
Historical Data
|
2020 - 2024
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Type, Treatment Type, End-User, and Region |
Geographies Covered |
North America, Europe, AsiaPacific, and the Rest of the World |
Countries Covered |
The US, German, France, UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil |
Key Companies Profiled |
 Bayer AG (Germany), SUPERFEET WORLDWIDE, LLC (U.S.), Bauerfeind USA Inc. (Germany), Ottobock (Germany), Recover Sports Medicine (Australia), Shapecrunch (India), 3M (U.S.), OrthoBethesda (U.S.), Apothecary Products, LLC (U.S.), |
Key Market Opportunities |
Weight and obesity are well-known concerns in contemporary civilizations across the globe. |
Key Market Dynamics |
Growing Number of Elderly People to drive market growth |
Frequently Asked Questions (FAQ):
In 2022, the market for treatments for plantar fasciitis was estimated to be worth USD 1.2 billion.
From 2025 to 2034, the market is expected to expand at a compound annual growth rate (CAGR) of 23.50%.
North America held the most market share worldwide.
Bauerfeind USA Inc. (Germany), Ottobock (Germany), SUPERFEET WORLDWIDE, LLC (U.S.), and Bayer AG (Germany) are the major participants in the market. Recover Sports Medicine (Australia).
In 2022, the market was dominated by the Medication Therapy category.
The market share held by orthotic devices was the highest.